Recent Advances in mRNA Vaccine Development

Aga Am
{"title":"Recent Advances in mRNA Vaccine Development","authors":"Aga Am","doi":"10.23880/oajmb-16000275","DOIUrl":null,"url":null,"abstract":"Messenger RNA vaccines are vaccine that utilizes a small segment of genetic material, messenger RNA (mRNA), to provide instructions to cells to produce a specific protein. This mRNA is synthesized in a laboratory and packaged into lipid nanoparticles, which protect and facilitate its entry into cells for protein synthesis. Upon injection into the muscle of the recipient, the mRNA instructs cells to produce a protein that is displayed on the surface of the cell, triggering an immune response. The immune system then produces antibodies and activates immune cells to target and eliminate the protein, while also generating memory cells to respond quickly in the event of future pathogen encounters. Available mRNA vaccines, such as Pfizer-BioNTech and Moderna, were developed and authorized for emergency use within a year. These vaccines require extensive cold chain storage, antigen delivery, potential immune response variability optimization, and sophisticated manufacturing process. To improve their effectiveness, stability, and delivery, efforts are underway to explore next-generation mRNA vaccines. Research is focused on enhancing the stability of mRNA vaccines, particularly their temperature sensitivity, to facilitate easier storage and distribution. Self-amplifying mRNA vaccines are also being developed to generate multiple copies of mRNA within cells, potentially leading to a higher production of protein and a stronger immune response. Studies are also exploring new delivery systems using specialized nanoparticles and liposomes to specifically target certain immune cells. Additionally, the development of combination vaccines, including multiple mRNA sequences in single vaccine, is being investigated to protect against multiple strains or variants of particular pathogen simultaneously. Direct delivery of mRNA vaccines into the skin is being explored as a means of enhancing immune response and reducing the required vaccine dose. In summary, messenger RNA vaccines represent a promising new approach to vaccination, with ongoing research aimed at improving their effectiveness, stability, and delivery","PeriodicalId":257510,"journal":{"name":"Open Access Journal of Microbiology & Biotechnology","volume":"13 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Access Journal of Microbiology & Biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.23880/oajmb-16000275","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Messenger RNA vaccines are vaccine that utilizes a small segment of genetic material, messenger RNA (mRNA), to provide instructions to cells to produce a specific protein. This mRNA is synthesized in a laboratory and packaged into lipid nanoparticles, which protect and facilitate its entry into cells for protein synthesis. Upon injection into the muscle of the recipient, the mRNA instructs cells to produce a protein that is displayed on the surface of the cell, triggering an immune response. The immune system then produces antibodies and activates immune cells to target and eliminate the protein, while also generating memory cells to respond quickly in the event of future pathogen encounters. Available mRNA vaccines, such as Pfizer-BioNTech and Moderna, were developed and authorized for emergency use within a year. These vaccines require extensive cold chain storage, antigen delivery, potential immune response variability optimization, and sophisticated manufacturing process. To improve their effectiveness, stability, and delivery, efforts are underway to explore next-generation mRNA vaccines. Research is focused on enhancing the stability of mRNA vaccines, particularly their temperature sensitivity, to facilitate easier storage and distribution. Self-amplifying mRNA vaccines are also being developed to generate multiple copies of mRNA within cells, potentially leading to a higher production of protein and a stronger immune response. Studies are also exploring new delivery systems using specialized nanoparticles and liposomes to specifically target certain immune cells. Additionally, the development of combination vaccines, including multiple mRNA sequences in single vaccine, is being investigated to protect against multiple strains or variants of particular pathogen simultaneously. Direct delivery of mRNA vaccines into the skin is being explored as a means of enhancing immune response and reducing the required vaccine dose. In summary, messenger RNA vaccines represent a promising new approach to vaccination, with ongoing research aimed at improving their effectiveness, stability, and delivery
mRNA 疫苗开发的最新进展
信使核糖核酸疫苗是一种利用一小段遗传物质--信使核糖核酸(mRNA)--向细胞发出指令以产生特定蛋白质的疫苗。这种 mRNA 在实验室中合成,并封装在脂质纳米颗粒中,从而保护并促进其进入细胞进行蛋白质合成。注入受试者的肌肉后,mRNA 会指示细胞生产一种蛋白质,这种蛋白质会显示在细胞表面,从而引发免疫反应。免疫系统随后会产生抗体并激活免疫细胞,针对并消除蛋白质,同时产生记忆细胞,以便在将来遇到病原体时迅速做出反应。现有的 mRNA 疫苗,如辉瑞生物技术公司(Pfizer-BioNTech)和 Moderna,都是在一年内开发并获准紧急使用的。这些疫苗需要大量的冷链储存、抗原递送、潜在免疫反应变异性优化和复杂的生产工艺。为了提高疫苗的有效性、稳定性和递送,目前正在努力探索下一代 mRNA 疫苗。研究的重点是提高 mRNA 疫苗的稳定性,尤其是温度敏感性,以便于储存和分发。此外,还在开发自扩增 mRNA 疫苗,以便在细胞内生成多个 mRNA 副本,从而提高蛋白质产量,增强免疫反应。研究还在探索新的给药系统,使用专门的纳米颗粒和脂质体来特异性地靶向某些免疫细胞。此外,还在研究开发组合疫苗,包括在单一疫苗中加入多个 mRNA 序列,以同时预防特定病原体的多个菌株或变种。目前正在探索将 mRNA 疫苗直接输送到皮肤中,作为增强免疫反应和减少所需疫苗剂量的一种手段。总之,信使 RNA 疫苗是一种很有前途的疫苗接种新方法,目前正在进行的研究旨在提高其有效性、稳定性和递送性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信